Abstract Details

Title Tradipitant Effective in the Reduction of Vomiting Associated with Motion Sickness Across Varied Sea Conditions

Topic General Neurology

Presentation(s) S3 - General Neurology 1 (1:24 PM-1:36 PM)

Poster/Presentation
Number 003

Background Motion sickness is a common disorder affecting approximately 30% of travelers under usual circumstances. The sensory mismatch theory postulates that motion sickness is induced by a discordance between the visual, vestibular, and kinesthetic systems, leading to a constellation of symptoms including nausea and vomiting. Substance P activates NK1 receptors in the nucleus tractus solitarius inducing a cascade of symptoms. Tradipitant is a novel NK1 receptor antagonist being studied for the treatment of nausea and vomiting associated with motion sickness.

Objective The Motion Syros study was a multicenter, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of tradipitant for motion sickness.

Design/Methods The Motion Syros study was a multicenter, randomized, double-blind, placebo-controlled study where 365 participants embarked on boat trips under varied sea conditions and received tradipitant 170 mg, tradipitant 85 mg, or placebo. Participants evaluated their symptoms at thirty-minute intervals during the expedition.

Results Participants on tradipitant 170 mg or 85 mg had a significantly lower incidence of vomiting as compared to those on placebo across all boat trips (tradipitant 170 mg = 18.3%, tradipitant 85mg = 19.5%, placebo = 44.3%, p < .0001 for both dose comparisons against placebo, n = 365). A range of wave heights was represented across the various boat trips, eliciting variable degrees of severity of motion sickness and differing responses to tradipitant.

Conclusions Tradipitant has been confirmed to be effective in the reduction of vomiting associated with motion sickness across varied sea conditions with a range of wave heights. Motion sickness remains a significant unmet medical need, given existing treatments’ limitations in alleviating symptoms and their frequent adverse effects.

Authors/Disclosures
Vasilios M. Polymeropoulos, MD (Vanda Pharmaceuticals) PRESENTER	Dr. Polymeropoulos has received personal compensation for serving as an employee of Vanda Pharmaceuticals. An immediate family member of Dr. Polymeropoulos has received personal compensation in the range of $500,000-$999,999 for serving as an officer or member of the Board of Directors for Vanda. Dr. Polymeropoulos has stock in Vanda.
Margaret Bushman (Vanda Pharmaceuticals)	No disclosure on file
Dane Morgan	No disclosure on file
Elizabeth Sutherland (Vanda Pharmaceuticals)	No disclosure on file
Tanner Davis (Vanda Pharmaceuticals, Inc.)	No disclosure on file
Nikolas Pham (Vanda Pharmaceuticals)	No disclosure on file
Leah Kiely (Vanda Pharmaceuticals Inc.)	No disclosure on file
Abigail Goldberg	No disclosure on file
Raina Mourad (Vanda Pharmaceuticals Inc.)	No disclosure on file
Cameron Miller	No disclosure on file
Changfu Xiao	No disclosure on file
Christos Polymeropoulos	No disclosure on file
Gunther Birznieks (VandaPharma)	No disclosure on file
Mihael Polymeropoulos	No disclosure on file